Still, the economic and market outlook this year seems cloudier than usual, due largely to stiff tariff increases and policy ...

In patients with venous thromboembolism (VTE) who are candidates for oral anticoagulation, apixaban results in fewer ...

Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock.

Bristol-Myers Squibb Co. prevailed against investor allegations it misled them about a payout tied to Food and Drug ...

Among the safety stocks discussed by Cramer during the episode on May 14, Bristol-Myers Squibb Company (NYSE:BMY) was first ...